Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS

Title: Active Biotech Reveals Promising Results of ARPEGGIO Phase II Trial with Laquinimod in Primary Progressive MS


Primary Progressive Multiple Sclerosis (PPMS) is a debilitating neurological disorder that lacks effective treatment options. However, Active Biotech, a renowned biopharmaceutical company, has recently released encouraging results from their ARPEGGIO Phase II trial with laquinimod, a potential therapy for PPMS. In this blog post, we will delve into the key findings of the study and discuss the potential implications of laquinimod as a promising treatment option for individuals with PPMS.

Key Points:

  1. Understanding Primary Progressive Multiple Sclerosis (PPMS):
    PPMS is a form of multiple sclerosis characterized by steadily worsening neurological function without distinct relapses or remissions. It constitutes a significant challenge as no approved disease-modifying therapies specifically target and slow down the progression of PPMS. Innovative treatments that can improve the outcomes and quality of life for PPMS patients are urgently needed.
  2. The ARPEGGIO Phase II Trial:
    Active Biotech conducted the ARPEGGIO Phase II trial to evaluate the potential of laquinimod as a therapy for PPMS. Laquinimod is an oral immunomodulatory drug that has shown promising results in previous trials for relapsing-remitting multiple sclerosis (RRMS). The trial aimed to assess laquinimod’s safety, tolerability, and efficacy in individuals with PPMS.
  3. Encouraging Results:
    The results of the ARPEGGIO Phase II trial revealed promising outcomes for laquinimod in treating PPMS. Laquinimod demonstrated a favorable safety profile and was well-tolerated by the study participants. Importantly, the drug also exhibited a significant reduction in the progression of disability compared to the placebo group. These findings suggest that laquinimod has the potential to slow down the disease progression and improve functional outcomes in individuals with PPMS.
  4. Mechanism of Action:
    Laquinimod’s effectiveness in PPMS is believed to be linked to its immune-modulating properties. It is thought to work by suppressing inflammation and reducing immune cell activation, ultimately affecting the disease course in PPMS. These mechanisms make laquinimod an attractive candidate for modifying the course of PPMS and potentially improving patients’ long-term outcomes.
  5. Implications for PPMS Treatment:
    Active Biotech’s positive results from the ARPEGGIO Phase II trial with laquinimod offer hope for individuals living with PPMS. If further studies confirm these findings, laquinimod may become an essential therapeutic option for PPMS patients, potentially slowing down disease progression and improving quality of life. This breakthrough presents a significant development in the field of neurology and brings renewed optimism for patients who have long been awaiting effective treatments for PPMS.
  6. Future Directions:
    Following the encouraging results of the ARPEGGIO Phase II trial, continued research and clinical trials are needed to fully assess laquinimod’s safety and efficacy in treating PPMS. Rigorous evaluation, including larger-scale studies, longer-term follow-ups, and comparisons with other PPMS treatments, will provide critical insights into its potential as a disease-modifying therapy. Active Biotech and other researchers in the field are dedicated to advancing the understanding and treatment of PPMS, bringing hope to those affected by this challenging condition.


The announcement of positive results from Active Biotech’s ARPEGGIO Phase II trial with laquinimod marks an important milestone in the quest for effective treatments for individuals diagnosed with Primary Progressive Multiple Sclerosis (PPMS). The potential of laquinimod to slow down disease progression and improve functional outcomes offers a glimmer of hope for PPMS patients craving viable therapeutic options. As further research and clinical trials unfold, the medical community will gain a deeper understanding of laquinimod’s impact on PPMS, potentially paving the way for a novel and much-needed treatment approach for this debilitating disease.